Medical/Pharmaceuticals
Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy
CAMBRIDGE, Mass., July 14, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a collaboration a...
2024-07-15 10:12
1747
Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule
CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that onJuly 10, 2024, NASDAQ notified the Company that it has determined that for the...
2024-07-12 20:30
6915
Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress
TAIPEI and SAN DIEGO, July 12, 2024 /PRNewswire/ -- Senhwa Biosciences' new drug Pidnarulex (CX-5461) has demonstrated efficacy in treating various solid tumors with BRCA2 or PALB2 gene defects. The abstract of this clinical trial has been selected for presentation at the 2024 European Society fo...
2024-07-12 19:00
5334
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
BEIJING, July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it plans to change the ratio of its American d...
2024-07-12 04:00
4643
Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation
SEOUL, South Korea, July 11, 2024 /PRNewswire/ -- Medit, a global leader in dental 3D scanners and digital dentistry solutions, has appointedHan Ryu as its new CEO. Ryu brings with him over three decades of senior management experience in global medical device and healthcare companies, including ...
2024-07-11 21:00
3459
First Patient Dosed in Phase I Clinical Trial of YOLT-201
SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced today the successful enrollment of the first patient in the Phase I clinical trial of YOLT-201, its independently developed in vivo g...
2024-07-11 20:11
2282
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC
SHANGHAI, July 11, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tech...
2024-07-11 20:00
2691
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL)
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan ) and TheUniversity of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric...
2024-07-11 14:21
2564
ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'
* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. * Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue ...
2024-07-11 14:07
2738
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year t...
2024-07-10 13:30
4341
Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development
CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced
that Enabling Technologies Consortium (ETC) has awarded a two-year contract to
J-STAR to collaborate on "Co-processing Platform Technology."
2024-07-08 22:00
2282
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®
* Tergase® poised to capture a fair share of the global hyaluronidase market.
DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc.
2024-07-08 21:00
3577
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease
BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer's disease (AD). AD is the most frequent ...
2024-07-08 17:23
2236
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME
* The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. * DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-induced rat DR model. * This project further validates ...
2024-07-08 17:00
2378
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its ...
2024-07-08 16:28
2228
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial
SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical tri...
2024-07-08 13:41
2385
Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC)
CHENGDU, China, July 5, 2024 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (688302.SH), a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for HP518, an investi...
2024-07-05 21:00
5379
IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy
SHANGHAI and NANJING, China and SAN JOSE, Calif., July 5, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", H...
2024-07-05 16:30
4927
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
SAN FRANCISCO, July 5, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar), which is a synthetic biology-driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that ...
2024-07-05 16:07
2531
Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia
HANGZHOU, China, July 5, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase1b/2a trial ...
2024-07-05 15:56
4129
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 322 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 292 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09